Pfizer Inc. (FRA:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 126.21B |
| Revenue (ttm) | 53.69B |
| Net Income (ttm) | 8.41B |
| Shares Out | n/a |
| EPS (ttm) | 1.48 |
| PE Ratio | 15.01 |
| Forward PE | 8.66 |
| Dividend | 1.53 (6.91%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 32,848 |
| Average Volume | 14,413 |
| Open | 22.11 |
| Previous Close | 22.19 |
| Day's Range | 21.79 - 22.24 |
| 52-Week Range | 18.77 - 26.50 |
| Beta | n/a |
| RSI | 50.88 |
| Earnings Date | Nov 4, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Pfizer (PFE) Coverage Resumed by Citi with 'Neutral' Rating
Pfizer (PFE) Coverage Resumed by Citi with 'Neutral' Rating
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
Pfizer (PFE) Part of UK-US Drug Pricing Agreement
Pfizer (PFE) Part of UK-US Drug Pricing Agreement
Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, D...
2 Undervalued, High-Quality Companies to Buy Now and Hold Forever
Drug companies face fairly normal industry dynamics that can leave them unloved on Wall Street over short periods of time. Pfizer is facing a patent cliff and is making a big move to revamp its drug p...
This 7% Yielder Could Be a Top AI Play
A looming patent cliff in which Pfizer will lose patent exclusivity to a handful of drugs has combined with cratering revenue from COVID-19 treatments to drive Pfizer shares down 50% since 2022. Pfize...
3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio
Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-t...
Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters
Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in th...
Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December
This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Most of the dividend increases announced in the last two ...
After Hours Most Active for Nov 28, 2025 : HBI, NVDA, SNAP, NEOG, MOS, INTC, AAPL, PFE, QQQ, CCL, AVTR, MSFT
The NASDAQ 100 After Hours Indicator is down -1.79 to 25,433.1. The total After hours volume is currently 95,876,785 shares traded.The following are the most active stocks for the after hours session:...
8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills
Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project n...
8 Dividend Stocks Every Investor Should Consider
Dividend investing isn't just about yield -- payout ratio and growth potential matter too. Several of these companies have increased dividends for decades without interruption.
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years
Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its core business remains strong.
Final Trade: DAL, AXP, PFE, HMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Final Trade: DAL, AXP, PFE, HMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15 . Lyme disease is a bacterial infect...
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month
The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highest‑cost medications, resulting in substantial annual savings on presc...
Did Pfizer Just Say "Checkmate" to Novo Nordisk?
Pfizer has been trying to get in on the billion-dollar weight loss drug market. Novo Nordisk initially dominated this market but has been losing ground to Eli Lilly.
Pfizer (PFE) Sees Significant Options Activity in Latest Trading Session
Pfizer (PFE) Sees Significant Options Activity in Latest Trading Session
Is This the Best Value Stock to Buy While Markets Are Volatile?
Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.
Want Over $7,000 in Annual Dividends? Invest $25,000 in Each of These 4 Stocks.
Income investors have been forced to seek yield in new places as stocks bump up against all-time highs. This diversified basket of blue chip names currently delivers over 7% annual yield.